Drugs / FE 999326
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05704244 | Dec 2022 → Nov 2029 expected | urinary bladder cancer | Ferring Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FE 999326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05704244 ↗ |
| Route | Other | “instilled once every 3 months into the bladder via a urinary catheter” NCT05704244 ↗ |